Transfusion Therapy: A Coming-of-Age Treatment for Patients with Sickle Cell Disease

American Journal of Pediatric Hematology/Oncology

Volumn 23, Issue 4, 2001, Pages 197-202

  Reed, William ^a   Vichinsky, Elliott P ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; HETASTARCH; HYDROXYUREA; IRON;

BLOOD TRANSFUSION; ERYTHROCYTE TRANSFUSION; HEMOSIDEROSIS; HUMAN; LEUKOPENIA; MORBIDITY; NOTE; PRIORITY JOURNAL; SICKLE CELL ANEMIA; STEM CELL TRANSPLANTATION; TREATMENT INDICATION;

ADOLESCENT; ADULT; AGED; ANEMIA, SICKLE CELL; BACTEREMIA; BLOOD GROUP ANTIGENS; BLOOD SUBSTITUTES; BLOOD TRANSFUSION; CHELATION THERAPY; CHILD; CHILD, PRESCHOOL; ERYTHROCYTE TRANSFUSION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOSIDEROSIS; HIV INFECTIONS; HUMANS; HYDROXYUREA; IMMUNIZATION; INFANT; INFANT, NEWBORN; LIFE EXPECTANCY; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; NEONATAL SCREENING; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; VIREMIA;

EID: 0035005122     PISSN: 01928562     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200105000-00002     Document Type: Editorial

References (61)

1. Wolman IJ, Ward GW, Jackson RF. Trial of prophylactic blood transfusion in patients with sickle cell disease. Am Soc Hematol 1970:abstract 331.
2. Wolman IJ. 1905-1978. Clin Pediatr 1978:605.
3. Styles L, Vichinsky E. Effects of a long-term transfusion regimen on sickle cell related illness. J Pediatr 1994; 125:909-11.
4. Adams R, McKie V, Hsu L, et al. Prevention of first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998; 339:5-11.
5. Styles L, Schalkwijk C, Aarsman A, et al. Phospholipase A2 levels in acute chest syndrome of sickle cell disease. Blood 1996; 87:2573-8.
6. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death [see comments]. N Engl J Med 1994; 330:1639-44.
7. Cunningham G, Lorey F, Kling S, et al. Mortality among children with sickle cell disease identified by newborn screening during 1990-1994 in California, Illinois, and New York. MMWR Morb Mortal Wkly Rep 1998; 47:169-72.
8. Vichinsky EP, Styles LA, Colangelo LH, et al. Acute chest syndrome in sickle cell disease: clinical presentation and course. Blood 1997; 89:1787-92.
9. Moser F, Miller S, Bello J, et al. The spectrum of brain abnormalities in sickle cell disease: a report from the cooperative study of sickle cell disease. Am J Neuroradiol 1996; 17:965-72.
10. Armstrong F, Thompson R, Wang W, et al. Cognitive functioning and brain magnetic resonance imaging in children with sickle cell disease. Pediatrics 1996; 97:864-70.
11. Styles LA, Vichinsky EP. Core decompression in avascular necrosis of the hip in sickle-cell disease. Am J Hematol 1996; 52:103-7.
12. Mukisi-Mukaza M, Elbaz A, Samuel-Leborgne Y, et al. Prevalence, clinical features, and risk factors of osteonecrosis of the femoral head among adults with sickle cell disease. Orthopedics 2000; 23:357-63.
13. Mantadakis E, Cavender JD, Rogers ZR, et al. Prevalence of priapism in children and adolescents with sickle cell anemia. J Pediatr Hematol Oncol 1999; 21:518-22.
14. Smith JA, Espeland M, Bellevue R, et al. Pregnancy in sickle cell disease: experience of the Cooperative Study of Sickle Cell Disease. Obstet Gynecol 1996; 87:199-204.
15. Styles L, Lubin B, Vichinsky E, et al. Decrease of very late activation antigen 4 and CD36 on reticulocytes in patients treated with hydroxyurea. Blood 1997; 89:2554-9.
16. Charache S, Terrnin M, Moore R. Effect of hydroxyurea on the frequency of painful crisis in sickle cell disease. N Engl J Med 1995; 322:1317-22.
17. Ferster A, Vermylen C, Cornu G, et al. Hydroxyurea for the treatment of sickle cell anemia: a pediatric clinical trial. Blood 1996; 88:1960-4.
18. Jayabose S, Tugal O, Sandoval C, et al. Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia. J Pediatr 1996; 129:559-65.
19. Ware RE, Zimmerman SA, Schultz WH. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood 1999; 94:3022-6.
20. Ware RE, Steinberg MH, Kinney TR. Hydroxyurea: an alternative to transfusion therapy for stroke in sickle cell anemia. Am J Hematol 1995; 50:140-3.
21. Vichinsky E, Lubin B. A cautionary note regarding hydroxyurea in sickle cell disease. Blood 1994; 83:1124-8.
22. Walters MC, Storb R, Patience M, et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Blood 2000; 95:1918-24.
23. Vermylen C, Cornu G. Bone marrow transplantation for sickle cell disease: the European experience. Am J Pediatr Hematol Oncol 1994; 16:18-21.
24. Walters MC, Patience M, Leisenring W, et al. Bone marrow transplantation for sickle cell disease. N Engl J Med 1996; 335:369-76.
25. Gore L, Lane PA, Quinones RR, et al. Successful cord blood transplantation for sickle cell anemia: implications for comprehensive care. Am J Pediatr Hematol Oncol 2000; 22 (5):437-40.
26. Brochstein J, Reed W, Smith RS, et al. Sibling-donor cord blood transplantation in a 23 month old with severe sickle cell disease. In: National Sickle Cell Disease Program; 2000; Philadelphia. Abstract.
27. Walters MC, Sullivan KM, Bernaudin F, et al. Neurologic complications after allogeneic marrow transplantation for sickle cell anemia. Blood 1995; 85:879-84.
28. Miller ST, Sleeper LA, Pegelow CH, et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med 2000; 342:83-9.
29. Serjeant GR. Natural history and determinants of clinical severity of sickle cell disease. Curr Opin Hematol 1995; 2:103-8.
30. Styles LA, Hoppe C, Klitz W, et al. Evidence for HLA-related susceptibility for stroke in children with sickle cell disease. Blood 2000; 95 (11):3562-7.
31. Vichinsky EP. Understanding the morbidity of sickle cell disease (letter). Br J Haematol 1997; 97:974-82.
32. Serjeant GR. Chronic transfusion programmes in sickle cell disease: problem or panacea? Br J Haematol 1997; 97:253-5.
33. Cohen AR. Sickle cell disease: new treatments, new questions (editorial). N Engl J Med 1998; 339:42-4.
34. Reed WF, Vichinsky EP. Transfusion practice for patients with sickle cell disease. Curr Opin Hematol 1999; 6:432-6.
35. Olivieri NF, Saxon BR, Nisbet-Brown E, et al. Quantitative assessment of tissue iron in patients with sickle cell disease. Blood 1997; 90:445a.
36. Brittenham GM, Cohen AR, McLaren CE, et al. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol 1993; 42:81-5.
37. Pippard MJ. Iron overload and iron chelation therapy in thalassaemia and sickle cell haemoglobinopathies. Acta Haematol 1987; 78:206-11.
38. Natta C, Creque L, Navarro C. Compartmentalization of iron in sickle cell anemia: an autopsy study. Am J Clin Pathol 1985; 83:76-8.
39. Peterson CM, Graziano JH, de Ciutiis A, et al. Iron metabolism, sickle cell disease, and response to cyanate. Blood 1975; 46:583-90.
40. Olivieri N, Nisbet-Brown E, Srichairatanakool S, et al. Studies of iron excretion and non-transferrin-bound plasma iron (NTBPI) following a single infusion of hydroxyethyl starch desferrioxamine (HES-DFO): a new approach to iron chelation therapy. Blood 1996; 88:310a.
41. Bergeron RJ, Wiegand J, Brittenham GM. HBED: the continuing development of a potential alternative to deferoxamine for iron-chelating therapy. Blood 1999; 93:370-5.
42. Olivieri NF, Brittenham GM, McLaren CE, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998; 339:417-23.
43. Adams D, Schultz W, Ware R, et al. Erythrocytapheresis can reduce iron overload and prevent the need for chelation in chronically transfused pediatric patients. J Pediatr Hematol Oncol 1996; 18:46-50.
44. Rosse W, Gallagher D, Kinney T. Transfusion and alloimmunization in sickle cell disease. Blood 1990; 76:1431-7.
45. Vichinsky E, Earles A, Johnson R. Alloimmunization in sickle cell disease and the transfusion of racially unmatched blood. N Engl J Med 1990; 322:1617-21.
46. Ambruso D, Githens J, Alcorn R, et al. Experience with donors matched for minor blood group antigens in patients with sickle cell anemia who are receiving chronic transfusion therapy. Transfusion 1987; 27:94-8.
47. Castellino SM, Combs MR, Zimmerman SA, et al. Erythrocyte autoantibodies in paediatric patients with sickle cell disease receiving transfusion therapy: frequency, characteristics and significance. Br J Haematol 1999; 104:189-94.
48. Reed W, Walker P, Haddix T, et al. Acute anemic events in sickle cell disease (clinical conference). Transfusion 2000; 40:267-73.
49. Klein HG, Dzik S, Slichter SJ, et al. Leukocyte-reduced Blood Components: Current Status. In: American Society of Hematology Education Program Book; 1998; Washington, DC. pp. 154-77.
50. AuBuchon JP, Birkmeyer JD, Busch MP. Safety of the blood supply in the United States: opportunities and controversies. Ann Intern Med 1997; 127:904-9.
51. Schreiber G, Busch M, Kleinman S, et al. The risk of transfusion-transmitted viral infections. N Engl J Med 1996; 334:1685-90.
52. Busch MP. Nucleic acid testing of blood donors for transfusion-transmitted infectious diseases: report of the interagency task force on nucleic acid amplification testing of blood donors. Transfusion 2000; 40 (10):1157-60.
53. McCullough J, Bianco C, Busch M, et al. Interagency Genome Amplification Testing Task Force: preliminary report (editorial). Transfusion 1998; 38:903-4.
54. Murthy KK, Henrard DR, Eichberg JW, et al. Redefining the HIV-infectious window period in the chimpanzee model: evidence to suggest that viral nucleic acid testing can prevent blood-borne transmission. Transfusion 1999; 39:688-93.
55. Blajchman MA. Bacterial contamination and proliferation during the storage of cellular blood products. Vox Sang 1998; 74:155-9.
56. McQuiston JH, Childs JE, Chamberland ME, et al. Transmission of tick-borne agents of disease by blood transfusion: a review of known and potential risks in the United States. Transfusion 2000; 40:274-84.
57. Wells GM, Woodward TE, Fiset P, et al. Rocky mountain spotted fever caused by blood transfusion. JAMA 1978; 239:2763-5.
58. Kleinman S, Lugo J, Litty C, et al. Transfusion-transmitted malaria. MMWR Morb Mortal Wkly Rep 1999; 48:254-6.
59. Lin L, Cook DN, Wiesehahn GP, et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997; 37:423-35.
60. Grass JA, Wafa T, Reames A, et al. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood 1999; 93:3140-7.
61. Murad KL, Mahany KL, Brugnara C, et al. Structural and functional consequences of antigenic modulation of red blood cells with methoxypoly (ethylene glycol). Blood 1999; 93:2121-7.